933671-86-4Relevant articles and documents
COMPOUNDS AND METHODS OF USE
-
Paragraph 0707-0708, (2021/05/07)
Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X1, X2, X3, X4, X5, A, L, R1, R2, R5, m and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS
-
Page/Page column 146, (2016/07/27)
Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, or their use in therapy.
BTK INHIBITORS
-
Page/Page column 146, (2016/07/27)
Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.
TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS
-
Page/Page column 84-85, (2016/08/03)
Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, or their use in therapy.
BTK INHIBITORS
-
Page/Page column 49, (2016/07/27)
Provided are imidazo[1,5-a]pyrazine derivatives according to Formula I, or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of imidazo[1,5-a]pyra
BTK INHIBITORS
-
Page/Page column 45, (2016/08/03)
The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.
BTK INHIBITORS
-
Page/Page column 58, (2015/07/07)
The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or pharmaceutically acceptable salts thereof. Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising the
TRIAZOLOPYRIDINES
-
Page/Page column 97-98, (2012/11/07)
The present invention relates to triazolopyridine compounds of general formula (I) : in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said com
SUBSTITUTED TRIAZOLOPYRIDINES
-
Page/Page column 94, (2012/12/13)
The present invention relates to substituted triazolopyridine compounds of general formula (I) : in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease such as tumours and proliferative diseases, as well as to intermediate compounds useful in the preparation of said compounds.
TRIAZOLOPYRIDINE DERIVATIVES
-
Page/Page column 87-88, (2011/06/23)
The present invention relates to triazolopyridine compounds of general formula (I) which are Monopolar Spindle 1 kinase (Mps-1 or TTK) inhibitors in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of proliferative diseases, as well as to intermediate compounds useful in the preparation of said compounds.
